相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma
Nouf Alrasheed et al.
CLINICAL CANCER RESEARCH (2020)
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
Hareth Nahi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
Christie P. M. Verkleij et al.
CANCERS (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Evaluating the role of Tregs in the progression of multiple myeloma
Deepesh Lad et al.
LEUKEMIA & LYMPHOMA (2019)
Phase 1b trial of pembrolizumab monotherapy for relapsed/ refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
Eileen M. Boyle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al.
LANCET HAEMATOLOGY (2019)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models
Natalie A. Bezman et al.
CANCER RESEARCH (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy
Matthew M. Gubin et al.
CELL (2018)
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Tomas Jelinek et al.
FRONTIERS IN IMMUNOLOGY (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients
Paola Neri et al.
BLOOD (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Takeru Asano et al.
BLOOD (2017)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs
L. E. Franssen et al.
BONE MARROW TRANSPLANTATION (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
From Truly Naive to Exhausted Senescent T Cells: When Markers Predict Functionality
Anis Larbi et al.
CYTOMETRY PART A (2014)
Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
Tyce J. Kearl et al.
JOURNAL OF IMMUNOLOGY (2013)
Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
Karthick Raja Muthu Raja et al.
PLOS ONE (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Malignant B Cells Induce the Conversion of CD4+CD25- T Cells to Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma
Yixiang Han et al.
PLOS ONE (2011)
The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
Shoba Amarnath et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
分享论文
